Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) | PAR 21 123

Frequently Asked Questions (FAQs)

What is NIH PAR-21-123 (IGNITE) focused on?

PAR-21-123, titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)," supports projects that build and rigorously validate model systems for neurological or neuromuscular disorders. The point is to make early-stage neurotherapeutic discovery more predictive and clinically meaningful by improving how well preclinical and ex vivo systems reflect real disease biology.

What is the main problem this funding opportunity is trying to solve?

The FOA is aimed at a common translational bottleneck: model systems that do not mirror human disease well enough to reliably predict whether a therapy will work in patients. By funding development and validation of more disease-relevant models, NIH is trying to strengthen early go/no-go decisions and reduce late-stage failures.

What kinds of model platforms does the FOA encourage?

The FOA encourages two broad categories: (1) animal models and (2) human/animal tissue ex vivo systems. In both categories, the expectation is that the proposed system will capture key aspects of a clearly defined neurological or neuromuscular disorder.

What does NIH mean by "rigorously validate" a model system in this FOA?

Based on the information provided, validation is expected to go beyond superficial resemblance or limited face validity. The model should recapitulate key phenotypic and physiologic characteristics of the disorder, including measurable functional impairments, relevant cellular or circuit-level dysfunction, and physiological readouts that map to observations in patients.

How important is translational relevance for proposed models?

Translational relevance is central. The FOA emphasizes that models should not only be scientifically interesting, but should also enable testing that is informative for therapeutic development decisions. That means building systems where biology and endpoints meaningfully correspond to the human disorder.

What kinds of endpoints or readouts are expected in the model?

The FOA highlights endpoints that are robust and interpretable, and ideally aligned with measures used (or usable) in clinical contexts. The model should be able to detect treatment effects following therapeutic intervention using disease-relevant functional and physiological readouts.

Is the goal to fund a therapeutic candidate or a clinical study?

No. The intended output is not necessarily a therapeutic candidate and not a clinical study. The FOA is positioned as support for developing and validating improved model systems or ex vivo platforms that can later be used to test interventions in ways that are more predictive of patient benefit.

Are clinical trials allowed under this opportunity?

No. The FOA is explicitly labeled "Clinical Trial Not Allowed." The supported work should focus on preclinical model systems and ex vivo validation activities rather than clinical trials in human participants.

What is the NIH activity code/mechanism for this award?

This opportunity uses the R61/R33 phased innovation award mechanism. It is described as milestone-driven, generally with an initial phase focused on development and early validation, followed by a subsequent phase that expands validation after predefined criteria are met.

How does the phased R61/R33 structure affect project planning?

Because it is milestone-driven, projects should be framed as progressing from development/early validation activities into expanded validation once performance and rigor criteria are achieved. The source text does not provide the detailed milestone structure, so applicants would need to consult the full FOA for specifics.

Which disorders or disease areas are relevant?

The FOA is focused on neurological or neuromuscular disorders. Proposals are expected to target a clearly defined disorder and build a model that recapitulates key disease-relevant features.

What is meant by improving the "predictiveness" of early-stage neurotherapeutic discovery?

In this FOA, predictiveness refers to whether results from a model system are more likely to translate into meaningful patient benefit. NIH is emphasizing models and ex vivo systems that reflect real disease biology and provide endpoints that better inform therapeutic development decisions.

What is the relationship of this FOA to the IGNITE program?

This opportunity is positioned within the IGNITE program, which is designed to accelerate exploratory and early drug discovery by supporting foundational enabling tools. Here, the enabling tools are better, validated disease-relevant model systems for neurotherapeutic discovery.

What is the funding category and agency for this opportunity?

It is a discretionary grant under the National Institutes of Health (NIH) within the health funding activity category.

What CFDA number is associated with this grant opportunity?

The opportunity is associated with CFDA number 93.853.

What is the listed closing date for the opportunity?

The original closing date listed in the provided information is 2024-10-21.

Is there an award ceiling or a set number of awards listed in the provided information?

No. The source information provided does not specify an award ceiling or the anticipated number of awards. Applicants would need to consult the full FOA and any associated NIH notices for current details.

Who is eligible to apply based on the information provided?

Eligibility includes, at minimum, nonprofits with 501(c)(3) status other than institutions of higher education. The FOA also notes a broad range of other eligible applicant types, including Alaska Native and Native Hawaiian Serving Institutions; AANAPISIs; eligible federal agencies; faith-based or community-based organizations; Hispanic-serving institutions; HBCUs; Indian/Native American tribal governments (other than federally recognized); foreign (non-U.S.) entities; regional organizations; TCCUs; and U.S. territories or possessions.

Are foreign (non-U.S.) entities allowed to apply?

Yes. The FOA notes foreign (non-U.S.) entities among eligible applicant types.

Does the FOA support collaborations across different organization types and geographies?

The eligibility list includes a wide range of organization types and includes foreign entities and U.S. territories or possessions, which signals an intent to draw model-development capacity from diverse settings and geographies.

What should a strong project deliver by the end of the award?

Based on the information provided, a strong project would deliver a demonstrably improved, rigorously validated animal model or ex vivo tissue system that recapitulates key disease biology and includes robust endpoints suitable for assessing efficacy after therapeutic intervention in a way that is informative for downstream neurotherapeutic development.

Does the FOA emphasize any particular scientific features in models beyond "face validity"?

Yes. The FOA emphasizes capturing important disease-relevant features such as measurable functional impairments, relevant cellular or circuit-level dysfunction, and physiological readouts that map onto what is observed in patients.